“In 2021, in the regulatory measures provided for in the social security financing law (LFSS), actions on drug prices represent 640 million euros, hence the need for precise, regular and shared, ”explained the Cegedim subsidiary in its press release.
To answer this, GERS Data launched Mediprim.
“Updated every month, the study [basée sur les données de l’assurance maladie, NDLR] provides for the city and for the hospital the amount of the execution to date of the decreases and increases of PFHT [prix fabricant hors taxes] and the estimated amount of the impact for the end of the year. The carry-over effect of price changes applied the previous year is also recognized. “
Mediprim thus offers “a consolidated and individualized reading for a given laboratory, segmented by type of product, by therapeutic class, by price variation bracket”. The study also offers the possibility of carrying out specific analyzes thanks to customizable selections such as the choice of a laboratory, a therapeutic class or a product.
“Mediprim responds to a real expectation of manufacturers because it makes it possible to measure the contribution of a laboratory to the regulatory effort and to prepare price negotiations with the Economic Committee for Health Products (CEPS). Available the following month and integrating the new prices as soon as they are published in the Official Journal, for an impact calculation from the date of application, the various monitoring indicators are accessible to all users for a view of all the laboratories “, specified Patrick Oscar, CEO of GERS Data, quoted in the press release.